Together, we concluded that INSL5 could enhance key glycolytic gene expression with a concomitant increase in metabolic intermediates (Fig EV3F), indicating that INSL5 mediates glycolytic reprogramming in cancer cells. The gene discussed is INSL5; the disease is cancer.